Share on LinkedInShare on LinkedIn

ARTICLE · 20 JUNE 2022

U.S. Senators Request PTO Action On Patent Thickets

On June 8, 2022, a bipartisan group of U.S. Senators sent a letter to Kathi Vidal, Director of the U.S. Patent & Trademark Office, requesting that the PTO take action on patent thickets.

United StatesIntellectual Property

On June 8, 2022, a bipartisan group of U.S. Senators sent a letter to Kathi Vidal, Director of the U.S. Patent & Trademark Office, requesting that the PTO take action on patent thickets. According to the Senators, "large numbers of patents cover a single product or minor variations on a single product, commonly known as patent thickets" that "negatively impacts millions of Americans." The Senators quoted a recent statement by President Biden that patent thickets "have been misused to inhibit or delay—for years and even decades—competition from generic drugs and biosimilars, denying Americans access to lower cost drugs." According to the Senators, "[i]n the drug industry, with the most minor, even cosmetic, tweaks to delivery mechanisms, dosages, and formulations, companies are able to obtain dozens or hundreds of patents for a single drug," and "[t]his practice impedes generic drugs' production, hurts competition, and can even extend exclusivity beyond

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from